Download het volledig rapport (302 p.) - KCE

More documents

Recommendations

Info

<strong>KCE</strong> reports vol. 6A Prenatale zorg 154 Study Ref Population Intervention Outcomes Results Comments Study type September 1997 to Serum samples also tested at birth weight) in outcomes between November 1999 (556 reference laboratory by TPHA. seronegative vs. the two groups: 17.3 RPR positive and 1132 FTA assay performed on sera that women treated for vs. 15.2 for all RPR negative) gave conflicting results from RPR and TPHA syphilis outcomes (p = 0.86) No significant difference in mean birth weight between the two groups (p = 0.24) Is it cost effective to undertake universal screening for syphilis infection in pregnant women in the UK? Study Ref Population Intervention Outcomes Results Comments Study Conner et al., 2000 4 [602] Data provided by 8 laboratories that performed a total of 169,140 antenatal screening tests for syphilis in one year, approximately one-fifth of the number of antenatal tests conducted in the UK Estimation of costs based on the assumption that 40 women a year are detected and treated through antenatal screening and that the number of screening tests performed equalled the number of live births in the UK (annual births 750,000) Cost of screening in the UK based on the cost of screening tests, treatment, and follow-up of infected women and their infants Costs of screening estimated to be £672,366 (£161,849 to £2,306,382), or £0.90 per pregnancy screened NNT = 18,602 women screened to detect one woman who needs treatment for syphilis and a maximum of 55,713 women need to be screened to prevent one case of congenital syphilis. This is the equivalent of £16,670 for each woman treated for syphilis, or £49,928 for each case of congenital syphilis prevented Targeted screening of high risk groups would detect 70% of cases but would be practically difficult. Costs for targeted screening strategies are also presented for women in the Thames region, pregnant women in nonwhites ethnic groups and women born outside the UK. Targeting or stopping screening would save relatively little money. type EL EL
<strong>KCE</strong> reports vol. 6A Prenatale zorg 155 2. k. Toxoplasmosis What is the toxoplasma susceptibility in women in Belgium Study Ref Population Intervention Outcomes Results Comments Study Donders et al., 1997 Vandekerc khove et al., 1996 65 1340 eligible women presenting for routine prenatal care at Gasthuisberg University Hospital in Leuven, Belgium during 1993 80 318 girls aged between 12 and 18 years in Flanders At the beginning of pregnancy a routine screening was offered in one single bloodtube for the following: - Anti-CMV IgG (1043 women were screened) - Anti-rubella IgG (1268 women were screened) - HbsAg (1278 women were screened) - Anti-HIV IgG (1057 women were screened) - Rapid Plasma reagent (RPR/ 1277 women were screened) - Anti-Toxoplasma IgG (1340 women were screened) Microparticle Enzyme Immunoassay (MEIA) to detect IgG against toxoplasma Toxoplasma susceptibility Prevalence of anti-CMV IgG: 16% at age 18 and 50% at age 40 (mean 28.3%) Deficient immunity against rubella: 15/1268 (1.2%) HBsAg carriership 0.23% No HIV infection detected Past infection with treponema pallidum occurred in 0.31% (RPR
Page 1 and 2:
NATIONALE RICHTLIJN PRENATALE ZORG:
Page 3 and 4:
Nationale richtlijn prenatale zorg:
Page 5 and 6:
KCE reports vol. 6A Prenatale zorg
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134: KCE reports vol. 6A Prenatale zorg
Page 183: KCE reports vol. 6A Prenatale zorg
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
This page is left intentionally bla
Page 301:
KCE reports 1. Effectiviteit en kos
show all

Download het volledig rapport (302 p.) - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?